You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 47 No. 5, May 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Frontal lobe function in progressive supranuclear palsy

J. Grafman, I. Litvan, C. Gomez and T. N. Chase
Cognitive Neuroscience Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892.

Performance on tasks evaluating "executive and attentional" processes presumably subserved by prefrontal cortex were compared in patients with progressive supranuclear palsy and with age- and education-matched control subjects. The results indicated that patients with progressive supranuclear palsy were particularly impaired when a task required sequential movements, conceptual shifting, monitoring the frequency with which stimuli are presented, or rapid retrieval of verbal knowledge. These deficits could not simply be accounted for by slowed information processing or by a deficit in representational knowledge. Conceivably, "weak activation" of frontal lobe representational knowledge characterized by an observed attentional deficit results in the neuropsychological impairments noted in patients with progressive supranuclear palsy. The oral administration of physostigmine, under double-blind placebo-controlled conditions, did not facilitate executive or attentional performance as evaluated by our tasks.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy
Brenneis et al.
J. Neurol. Neurosurg. Psychiatry 2004;75:246-249.
ABSTRACT | FULL TEXT  

Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy
Litvan et al.
Neurology 2001;57:467-473.
ABSTRACT | FULL TEXT  

Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy
Soliveri et al.
J. Neurol. Neurosurg. Psychiatry 2000;69:313-318.
ABSTRACT | FULL TEXT  

Progressive supranuclear palsy
Rehman
Postgrad. Med. J. 2000;76:333-336.
ABSTRACT | FULL TEXT  

PET measures of benzodiazepine receptors in progressive supranuclear palsy
Foster et al.
Neurology 2000;54:1768-1773.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.